Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., Research Square, doi:10.21203/rs.3.rs-72132/v1 (Preprint)
Pre-exposure prophylaxis with hydroxych loroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial
Small PrEP RCT showing that PrEP with HC
Q is safe at the dosage used. No deaths, hospitalizations, or serious adverse events. With only one case (in the placebo arm), efficacy was not evaluated.
COVID-19 case, ↓70.2%, p=0.47
Please send us corrections, updates, or comments.